Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
SBC Medical Group Holdings, Inc. (SBC)
NASDAQIndustrialsConsulting ServicesSnapshot 2026-11-04
$5.32+2.11%
Close 2026-11-04 · 1-day change
NASDAQIndustrialsConsulting ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.52 → 0.52 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SBC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain positive net income trajectory | The company maintains a positive net income trajectory with $11.3M in Q1 2026. | Under Pressure | Net income falls below $8M in any quarter in 2026 | Net income: $10.693M FY2026-Q2; GAAP. Published target: Net income remains positive and stable around $11M+ per quarter through 2026. Target period is not explicitly aligned with this observation. Aug 13, 202610,692,822 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This investment represents a speculative growth opportunity. The company is focusing on enhancing services through AI and expanding its multi-brand strategy, which aligns with its recent strong performance.
The current valuation suggests that the market views SBC as cheap compared to its peers. However, there is a notable expectations gap, indicating that investors are cautious about the company's fragile earnings quality and recent execution issues.
Management's execution on growth priorities appears to be on track, as evidenced by strong revenue and income growth. However, there is a near-term risk of missing earnings expectations, given the company's history of consecutive misses.
The long-term thesis hinges on SBC's ability to maintain momentum in the face of sector headwinds and the performance of industry bellwethers. Positive guidance from these peers could support SBC, while negative trends could pose risks.
Overall, SBC's fundamentals show promise, but the investment carries risks that need to be monitored closely. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Implement $20M share repurchase program |
| It has a $20 million share buyback program. |
| Intact |
| Buyback program not executed or materially delayed by end 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Expand into U.S. medical aesthetics market | medical aesthetics market. | Intact | No meaningful U.S. market entry or partnerships by end 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.48 → $0.52 · observed estimates
$0.19B → $0.21B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-07-25 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-07-26 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-07-27 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-07-28 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-07-29 | $0.48 | $196,295,500 | 2 / 4 |
| 2026-07-30 | $0.48 | $196,295,500 | 2 / 4 |
| 2026-07-31 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-01 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-02 | $0.48 | $196,295,500 | 2 / 4 |
| 2026-08-03 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-04 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-05 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-06 | $0.48 | $196,295,500 | 2 / 4 |
| 2026-08-08 | $0.48 | $196,295,500 | 2 / 4 |
| 2026-08-09 | $0.48 | $196,295,500 | 2 / 4 |
| 2026-08-10 | $0.48 | $196,295,500 | 2 / 4 |
| 2026-08-12 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-13 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-14 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-15 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-16 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-17 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-18 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-19 | $0.48 | $193,410,667 | 2 / 3 |
| 2026-08-20 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-21 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-22 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-23 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-24 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-25 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-26 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-27 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-28 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-29 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-30 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-08-31 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-01 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-02 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-03 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-04 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-05 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-06 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-07 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-08 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-09 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-10 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-11 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-12 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-13 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-14 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-15 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-16 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-17 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-18 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-19 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-20 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-21 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-22 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-23 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-24 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-25 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-26 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-27 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-28 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-29 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-09-30 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-01 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-02 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-03 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-04 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-05 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-06 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-07 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-08 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-09 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-10 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-11 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-12 | $0.52 | $206,274,667 | 2 / 3 |
| 2026-10-13 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-14 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-15 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-16 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-17 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-18 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-19 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-20 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-21 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-22 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-23 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-24 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-25 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-26 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-27 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-28 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-29 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-30 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-10-31 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-11-01 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-11-02 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-11-03 | $0.52 | $206,260,300 | 2 / 3 |
| 2026-11-04 | $0.52 | $206,260,300 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.